miR‑128 induces pancreas cancer cell apoptosis by targeting MDM4

Han,Hongchao; Wang,Lisheng; Xu,Jie; Wang,Aikun

doi:10.3892/etm.2018.6047

miR‑128 induces pancreas cancer cell apoptosis by targeting MDM4

Authors:
- Hongchao Han
- Lisheng Wang
- Jie Xu
- Aikun Wang
View Affiliations

Affiliations: Department of General Surgery, The Third People's Hospital, Yancheng, Jiangsu 224000, P.R. China, Department of Gynecology and Obstetrics, The Third People's Hospital, Yancheng, Jiangsu 224000, P.R. China
Published online on: April 10, 2018 https://doi.org/10.3892/etm.2018.6047
Pages: 5017-5022

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNA/miRs) are small, non‑coding RNA molecules (19‑25 nucleotides in length), which function to regulate gene expression. It has been reported that miR‑128 serves an important role in regulating cancer cell growth; increasing evidence has indicated that the expression of miR‑128 is decreased in pancreatic cancer (PC) cells. However, the specific mechanisms of miR‑128 in regulating PC cell growth are unclear. In the present study, it was confirmed that the expression of miR‑128 was significantly decreased within PC tissues compared with adjacent normal tissues via reverse transcription‑quantitative polymerase chain reaction analysis. In addition, miR‑128 mimics inhibited PC MIA‑PaCa2 cell growth by enhancing cell apoptosis in a caspase‑dependent manner. Furthermore, the results of the present study demonstrated that double minute 4 (MDM4) may be a direct target for miR‑128 via a dual luciferase report assay; miR‑128 may inhibit MDM4 expression, and increase p53 and cleaved caspase‑3 protein expression levels. In summary, the present study indicated that miR‑128 is downregulated in PC, and it may be a promising target for future PC diagnosis and treatment.

View Figures

View References

1	Vaz J, Ansari D, Sasor A and Andersson R: SPARC: A potential prognostic and therapeutic target in pancreatic cancer. Pancreas. 44:1024–1035. 2015. View Article : Google Scholar : PubMed/NCBI
2	Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L and Satolli MA: Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol. 7:27–43. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lin QJ, Yang F, Jin C and Fu DL: Current status and progress of pancreatic cancer in China. World J Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
4	Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J and Van Laethem JL: New challenges in perioperative management of pancreatic cancer. World J Gastroenterol. 21:2281–2293. 2015. View Article : Google Scholar : PubMed/NCBI
5	Davis JL, Pandalai PK, Ripley RT, Langan RC and Avital I: Expanding surgical treatment of pancreatic cancer: The role of regional chemotherapy. Pancreas. 41:678–684. 2014. View Article : Google Scholar
6	Rachagani S, Macha MA, Heimann N, Seshacharyulu P, Haridas D, Chugh S and Batra SK: Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev. 81:16–33. 2015. View Article : Google Scholar : PubMed/NCBI
7	Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB III, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, et al: Pancreatic Adenocarcinoma, version 2.2012: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 10:703–713. 2012. View Article : Google Scholar : PubMed/NCBI
8	Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, et al: Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results. J Clin Oncol. 31:886–894. 2013. View Article : Google Scholar : PubMed/NCBI
9	Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
10	Hao J, Zhang S, Zhou Y, Hu X and Shao C: MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett. 585:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
11	Khan S, Ansarullah DK, Kumar D, Jaggi M and Chauhan SC: Targeting microRNAs in pancreatic cancer: Microplayers in the big game. Cancer Res. 73:6541–6547. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yu J, Li A, Hong SM, Hruban RH and Giggins M: MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 18:981–992. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ali S, Saleh H, Sethi S, Sarkar FH and Philip PA: MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer. 107:1354–1360. 2012. View Article : Google Scholar : PubMed/NCBI
14	Huang J, Liu J, Chen-Xiao K, Zhang X, Lee WN, Go VL and Xiao GG: Advance in microRNA as a potential biomarker for early detection of pancreatic cancer. Biomark Res. 4:202016. View Article : Google Scholar : PubMed/NCBI
15	Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW and Peng CH: Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: Meta-analysis, experimental validation and clinical significance. J Exp Clin Cancer Res. 32:712013. View Article : Google Scholar : PubMed/NCBI
16	He H, Hao SJ, Yao L, Yang F, Di Y, Li J, Jiang YJ, Jin C and Fu DL: MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1. Cancer Biol Ther. 15:1333–1339. 2014. View Article : Google Scholar : PubMed/NCBI
17	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J, Zhou J, Wu J and Shao C: Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 32:1183–1189. 2011. View Article : Google Scholar : PubMed/NCBI
19	Munding JB, Adai AT, Maghnouj A, Urbanik A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, Tannapfel A and Hahn SA: Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer. 131:E86–E95. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhao C, Zhang J, Zhang S, Yu D, Chen Y, Liu Q, Shi M, Ni C and Zhu M: Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. Oncology Rep. 30:276–284. 2013. View Article : Google Scholar
21	Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y, Liu QH, Shi M, Ni CR and Zhu MH: Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. Oncol Re. 31:1157–1164. 2014. View Article : Google Scholar
22	Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K and Satoh K: Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol. 46:539–547. 2014. View Article : Google Scholar : PubMed/NCBI
23	Marine JC and Jochemsen AG: Mdmx as an essential regulator of p53 activity. Biochem Biolphys Res Commun. 331:750–760. 2005. View Article : Google Scholar
24	Gospodarowicz MK, Brierley JD and Wittekind C: TNM Classification of Malignant Tumours. 2017.
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delata Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
27	Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 33:698–709. 2009. View Article : Google Scholar : PubMed/NCBI
29	Lee KH, Lee JK, Choi DW, Do IG, Sohn I, Jang KT, Jung SH, Heo JS, Choi SH and Lee KT: Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. Pancreas. 44:764–768. 2015. View Article : Google Scholar : PubMed/NCBI